StatStrip Glucose’s wireless connectivity can transmit patient results directly from the patient bedside, alleviating the need to bring the meter to a fixed location for meter docking and data transmission. Wireless connectivity saves time for the caregiver and allows for faster charting of results and clinical decision making to improve patient care. StatStrip Glucose’s dual channel wireless connectivity provides complete security and encryption to ensure that patient data remains uncompromised. Nova now offers a full range of StatStrip Glucose wireless connectivity capabilities, including wireless meters, wireless carrying cases, and wireless docking stations. All of the wireless devices use industry standard POCT1-A2 data format and are compatible with a choice of middleware partners.

StatStrip Glucose is the only glucose meter cleared by the U.S. Food and Drug Administration (FDA) for use with all patients, in all healthcare settings, including critical care. StatStrip Glucose received this clearance in 2014 after an extensive, nearly four-year project conducted at five major university medical centers, which included 1,698 critically ill patients with over 257 clinical conditions, tested with over 8,000 medications in complex treatment regimens. StatStrip was found to have no clinically significant interferences.

In addition to the study submitted to the FDA, 138 other independent studies over the last eight years—including 53 critical care studies—have found no clinically significant interferences for StatStrip Glucose. This is a statement that no other glucose meter manufacturer can make. StatStrip Glucose is the world’s most extensively studied and proven glucose test.

About Nova Biomedical
Incorporated in 1976 and based in Waltham, MA, Nova Biomedical is a world leader in the development and manufacturing of state-of-the-art, whole blood, point-of-care and critical care analyzers, and is one of the fastest growing in vitro diagnostic companies in the world. Nova’s whole blood biosensor technology is incorporated in products ranging from handheld meters for glucose self- and point-of-care testing to critical care whole blood analyzers designed for rapid measurement of over 20 analytes. Nova employs over 1,000 people worldwide and has wholly owned subsidiaries located in Canada, France, Germany, Great Britain, Japan, and Taiwan. Certified by the International Organization for Standardization, Nova has manufacturing operations located in the U.S., Taiwan, and Brazil.